Clinical trials: Phase 1
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase I/II trial to study the effectiveness of liposomal daunorubicin and SU5416 in treating patients who have hematologic cancer that has not responded to initial therapy.
- Conditions
- Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
- Trial name
- NCT00005942
- Testing
- liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Onchocerciasis
Emodepside Phase II Trial for Treatment of Onchocerciasis
The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.
- Trial name
- NCT05180461
- Testing
- emodepside, ivermectin
- Where
- 3 sites in Democratic Republic of the Congo, Ghana
- Volunteers
- 578 people
- Sponsor
- Drugs for Neglected Diseases
Brain Injuries, Traumatic
Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration
The purpose of this study is to obtain evidence of safety and determine the pharmacokinetics (PK) of NNZ-2566 in healthy volunteers, when administered orally.
- Trial name
- NCT01420042
- Testing
- NNZ-2566
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neuren Pharmaceuticals Limited
COVID, Covid-19
Trial of Combination Therapy to Treat COVID-19 Infection
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
- Conditions
- COVID, Covid-19, Corona Virus Infection, Coronavirus Infection
- Trial name
- NCT04482686
- Testing
- Ivermectin, Doxycycline Hcl, Zinc
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- ProgenaBiome
Female Infertility
Multiple Dose FSH-GEX(TM) in Healthy Volunteers
The aim of the current study is the pharmacokinetic and pharmacodynamic characterization of a multiple dose administration of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator…
- Trial name
- NCT01477073
- Testing
- FSH-GEX™, recombinant FSH, urinary FSH
- Where
- Netherlands
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Glycotope GmbH
Waldenstrom Macroglobulinemia
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
The purpose of this study is to determine the recommended dose of lenalidomide in subjects with relapse and refractory Waldenstrom Macroglobulinemia.
- Trial name
- RV-WM-0426 (NCT02302469)
- Testing
- Revlimid
- Where
- 7 sites in France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Lille
Anemia
INTERCEPT Safety Evaluation in Anemic Patients
The pathogen reduction (PR) system for Whole Blood (WB) using Amustaline (S-303) and Glutathione (GSH) has a potential to decrease transfusion-transmitted infection.
- Trial name
- POINT1africa (NCT03486054)
- Testing
- INTERCEPT, Standard of Care
- Sponsor
- Swiss Transfusion SRC
Squamous Cell Carcinoma of Head and Neck
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04183166
- Testing
- TG4050
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Transgene
Pancreatic Cancer
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Four-drug combo yielded a statistically significant improvement in progression-free survival and overall survival compared to gemcitabine in patients with advanced pancreatic adenocarcinoma.
- Trial name
- PACT-19 (NCT01730222)
- Testing
- cisplatin, capecitabine, gemcitabine
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- IRCCS San Raffaele
Lymphoma, Non Hodgkin's Lymphoma
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
We now propose to investigate the combination of CHOP-Rituxan plus PEG-Filgrastim (PEG-filgrastim) and GM-CSF. PEG-Filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the…
- Trial name
- CHOP-R (NCT01527422)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Fernando Cabanillas
Advanced Solid Tumors
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.
- Trial name
- NCT06618651
- Testing
- SHR-3821 injection
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Non-alcoholic fatty liver disease (NAFLD) treatment drug HEC96719 in Healthy Male and Female Subjects
- Trial name
- NCT04422496
- Testing
- HEC96719
- Where
- Australia
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Recurrent Glioblastoma, Recurrent Malignant Glioma
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory).
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT02208362
- Testing
- Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- City of Hope Medical Center
Binge-Eating Disorder
Reduction of the Speed of Eating as an Intervention in Obesity
Patients diagnosed with Binge Eating Disorder (BED) overeat food but, as opposed to patients with bulimia nervosa, they do not compensate for their increased food intake and therefore their body weight increases.
- Trial name
- NCT02381327
- Testing
- Mandometer
- Where
- Sweden
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Mando Group AB
Neimann-Pick Disease
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence.
- Trial name
- NCT02124083
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Obesity, Overweight
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m^2 or higher or 24 kg/m^2 or higher with at least 1 weight related…
- Trial name
- NCT06214741
- Testing
- survodutide
- Where
- 28 sites in China
- Volunteers
- 307 people
- Sponsor
- Boehringer Ingelheim
Diabete Mellitus, Diabete Type 2
A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus
This Phase I clinical trial is a multi-center, single-arm, open-label study aimed at evaluating the safety and efficacy of RGB-5088 islet cell infusion in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT07794254
- Testing
- RGB-5088
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Reprogenix Bioscience, Inc
Lymphoma, Solid Tumor
Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of cancer cells, either…
- Trial name
- NCT00470405
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Drugs used in chemotherapy, such as arsenic trioxide and pamidronate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00124605
- Testing
- pamidronate disodium, arsenic trioxide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Subjects
A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects
The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed…
- Trial name
- NCT03215966
- Testing
- Macitentan / tadalafil FDC, Macitentan (Opsumit®), Tadalafil (Adcirca®)
- Where
- Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Actelion